| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
ATHA sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.53M | $9.71M | - | |
| CEO | 40.8K | $280.9K | - | |
| Other | 20.7K | $142.3K | - | |
| Other | 14.0K | $96.2K | - | |
| CFO | 12.9K | $88.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | San Martin Javier65 | Chief Medical Officer | Sale+OE | 1,644 | $6.88 | $11,310.72 | -13.9% | |
| Jan 2, 2026 | Renninger Robert | Chief Financial Officer | Sale+OE | 297 | $6.88 | $2,043.36 | -2.3% | |
| Jan 2, 2026 | Litton Mark James | President And CEO | Sale+OE | 2,586 | $6.88 | $17,791.68 | -6.0% | |
| Jan 2, 2026 | Church Kevin | Chief Scientific Officer | Sale+OE | 876 | $6.88 | $6,026.88 | -4.1% | |
| Jan 2, 2026 | Worthington Mark | General Counsel And CCO | Sale+OE | 876 | $6.88 | $6,026.88 | -5.9% | |
| Jul 1, 2025 | Renninger Robert | SVP, Finance And Accounting | Sale+OE | 2,897 | $0.29 | $850.27 | -2.6% | |
| Jul 1, 2025 | San Martin Javier65 | Chief Medical Officer | Sale+OE | 10,842 | $0.29 | $3,182.13 | -13.1% | |
| Jul 1, 2025 | Worthington Mark | General Counsel And CCO | Sale+OE | 8,526 | $0.29 | $2,502.38 | -7.1% | |
| Jul 1, 2025 | Litton Mark James | President And CEO | Sale+OE | 25,123 | $0.29 | $7,373.60 | -7.2% | |
| Jul 1, 2025 | Church Kevin | Chief Scientific Officer | Sale+OE | 8,526 | $0.29 | $2,502.38 | -4.8% |